Anti-LIRA1/ LILRA1/ CD85I monoclonal antibody
Anti-LIRA1/ LILRA1/ CD85I antibody for FACS & in-vivo assay
Go to LILRA1/LILRA1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP0731-Ab-1/ GM-Tg-hg-MP0731-Ab-2 | Anti-Human LILRA1 monoclonal antibody | Human |
| GM-Tg-rg-MP0731-Ab-1/ GM-Tg-rg-MP0731-Ab-2 | Anti-Rat LILRA1 monoclonal antibody | Rat |
| GM-Tg-mg-MP0731-Ab-1/ GM-Tg-mg-MP0731-Ab-2 | Anti-Mouse LILRA1 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP0731-Ab-1/ GM-Tg-cynog-MP0731-Ab-2 | Anti-Cynomolgus/ Rhesus macaque LILRA1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP0731-Ab-1/ GM-Tg-felg-MP0731-Ab-2 | Anti-Feline LILRA1 monoclonal antibody | Feline |
| GM-Tg-cang-MP0731-Ab-1/ GM-Tg-cang-MP0731-Ab-2 | Anti-Canine LILRA1 monoclonal antibody | Canine |
| GM-Tg-bovg-MP0731-Ab-1/ GM-Tg-bovg-MP0731-Ab-2 | Anti-Bovine LILRA1 monoclonal antibody | Bovine |
| GM-Tg-equg-MP0731-Ab-1/ GM-Tg-equg-MP0731-Ab-2 | Anti-Equine LILRA1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP0731-Ab-1/ GM-Tg-hg-MP0731-Ab-2; GM-Tg-rg-MP0731-Ab-1/ GM-Tg-rg-MP0731-Ab-2; GM-Tg-mg-MP0731-Ab-1/ GM-Tg-mg-MP0731-Ab-2; GM-Tg-cynog-MP0731-Ab-1/ GM-Tg-cynog-MP0731-Ab-2; GM-Tg-felg-MP0731-Ab-1/ GM-Tg-felg-MP0731-Ab-2; GM-Tg-cang-MP0731-Ab-1/ GM-Tg-cang-MP0731-Ab-2; GM-Tg-bovg-MP0731-Ab-1/ GM-Tg-bovg-MP0731-Ab-2; GM-Tg-equg-MP0731-Ab-1/ GM-Tg-equg-MP0731-Ab-2 |
| Products Name | Anti-LILRA1 monoclonal antibody |
| Format | mab |
| Target Name | LILRA1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-LILRA1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species LIRA1/ LILRA1/ CD85I VLP (virus-like particle) (Products Developing) |
Target information
| Target ID | GM-MP0731 |
| Target Name | LILRA1 |
| Gene ID | 11024,692342 |
| Gene Symbol and Synonyms | CD85I,LILRA1,LILRAA,LIR-6,LIR6 |
| Uniprot Accession | O75019 |
| Uniprot Entry Name | LIRA1_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000104974 |
| Target Classification | N/A |
The target: LILRA1, gene name: LILRA1, also named as CD85I, LIR-6, LIR6. This gene encodes an activating member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein is predominantly expressed in B cells, interacts with major histocompatibility complex class I ligands, and contributes to the regulation of immune responses. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, May 2013].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

